News
RDY
14.44
-1.33%
-0.20
Weekly Report: what happened at RDY last week (0629-0703)?
Weekly Report · 2d ago
Coya Therapeutics posts investor deck outlining Treg-directed combination therapy strategy for neurodegenerative diseases
PUBT · 07/01 12:50
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Benzinga · 07/01 08:20
Monday's ETF Movers: BUG, EMEQ
NASDAQ · 06/29 16:01
Weekly Report: what happened at RDY last week (0622-0626)?
Weekly Report · 06/29 10:06
BUZZ-India's Dr Reddy's rises as analysts project no material impact from US FDA observations
Reuters · 06/29 04:20
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Barchart · 06/26 10:10
BUZZ-Indian pharma stocks gain on US cancer drug shortage
Reuters · 06/25 05:41
Bullish Two Hundred Day Moving Average Cross - RDY
NASDAQ · 06/22 20:12
Dr. Reddy’s Sets July 22 Board Meet, Imposes Trading Blackout for Q1 FY27 Results
TipRanks · 06/22 17:57
Dr. Reddy’s Allots 6,730 ESOP Shares, Expands Issued Capital
TipRanks · 06/22 10:48
Dr. Reddy’s Announces 42nd AGM via Video Conference and Final Dividend Details
TipRanks · 06/22 10:47
Weekly Report: what happened at RDY last week (0615-0619)?
Weekly Report · 06/22 10:14
Analysts’ Top Healthcare Picks: Dr Reddy’s Laboratories (RDY), Amgen (AMGN)
TipRanks · 06/18 11:20
FOCUS-US progesterone supplies tighten as menopause treatment demand grows
Reuters · 06/17 10:00
Innoviva announces distribution, licensing agreement with Dr. Reddy’s
TipRanks · 06/16 12:15
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial Pneumonia
Benzinga · 06/16 12:05
Innoviva Specialty Therapeutics signs Dr. Reddy’s deal to distribute Xacduro in select international markets
PUBT · 06/16 12:01
Embecta names Nimish Muzumdar SVP, President North America
PUBT · 06/16 10:30
Dr. Reddy’s launches first-to-market generic Bosutinib 400mg in U.S. oncology market
TipRanks · 06/15 10:28
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.